Age: 86.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic, Skin mass, Sneezing
Clinical narrative: skin bumps all over her body; Itching rash; had an allergic reaction hypersensitivity/ sneezing; This spontaneous case was reported by a patient and describes the occurrence of SNEEZING (had an allergic reaction hypersensitivity/ sneezing), SKIN MASS (skin bumps all over her body) and RASH PRURITIC (Itching rash) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product DUPILUMAB solution for injection for Atopic dermatitis.    Previously administered products included for Atopic dermatitis: DUPILUMAB (Solution for injection Dose: 300 mg Frequency: QOW Route: Subcutaneous On 16 Oct 2020, the patient took dupilumab at a loading dose of 600 mg followed by maintenance dose of 300 mg every other week since 30 Oct 2020.) in August 2020, DUPILUMAB in August 2020 and DUPILUMAB in August 2020. Past adverse reactions to the above products included Drug use for unapproved dosing regimen with DUPILUMAB; Incomplete dose administered with DUPILUMAB; and Intentionally missed dose with DUPILUMAB. Concurrent medical conditions included Visual impairment.   On 30-Oct-2020, the patient started DUPILUMAB (Subcutaneous) 300 milligram every two weeks. On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced SNEEZING (had an allergic reaction hypersensitivity/ sneezing). On an unknown date, the patient experienced SKIN MASS (skin bumps all over her body) and RASH PRURITIC (Itching rash). At the time of the report, SNEEZING (had an allergic reaction hypersensitivity/ sneezing), SKIN MASS (skin bumps all over her body) and RASH PRURITIC (Itching rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient's past medical history, concomitant treatment(s) and family history were not provided.  No concomitant medications were reported. No lab test was reported.  Reported itching returned because she has not received any injection due to insurance issues and product use issue (nurse asked consumer if on the same day she was injected twice, she said no, she was injected one injection two weeks apart) and only took one syringe 300 mg instead of 600 for the loading dose.  It was reported by the patient that two to three days after the doctor injected her in the office her itching went away and she was very happy with dupilumab, but then the itching returned on Sunday that was on 04-0ct-2020 (pruritus, latency: approximately 1 month few days) because she had not received an injection since Aug-2020 due to insurance issues.  Nurse reported since 30Dec2020 being her last dose there has been a lapse in her therapy due to PAP approval then restarted on 08Mar2021. She received her second vaccine on 29Mar2021.  It was not reported if the patient received a corrective treatment for the events.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.